A year ago, Lund-based Aegirbio bought a covid test company for ten million kronor.
Ten months later, in the summer of 2021, Aegirbio reached a market capitalization of over six billion kronor.
Behind the price rally was several positive news about their rapid tests against covid-19.
On June 25, Aegirbio and their distribution partner announced a "trial order worth approximately SEK 100 million for delivery to Asia".
A few weeks later, new orders worth a total of SEK 800 million were announced.
In parallel with the company's news, the share rose on various stock exchange forums and on social media - and the number of shareholders grew rapidly.
On the online bank Avanza you can see how the number went from 12,000 at the beginning of July to 24,000 at the end of the month.
Rushed 400 percent
At the same time as investors flocked, the share rose sharply.
In just a few weeks, it was a rush of about 400 percent.
Since the peak at the end of July, the price has fallen - and only in the last week it is a race of almost 50 percent.
One reason for the sharp decline is an update from Aegirbio on Thursday morning with announcements of delays and a lower sales forecast than expected.
Problems with conditions
According to Aegirbio's CEO Martin Linde, approximately one million covid tests were sent to Thailand during the autumn - which is less than the company had hoped for.
- It has been more difficult to get the necessary permits from the authorities in the different countries, Linde says to SVT.
Aegirbio's share has at the same time been questioned on various stock forums.
SVT can now also reveal that among Aegirbio's partners there are several connections to players in the so-called mobile complex.
Do you know more? Tip SVT's reviewing reporters.